Background Osteoporosis is a common metabolic bone disease. We conducted a multi-center, double- placebo, double-blind study to verify the effects of calcium aspartate anhydrous on osteoporosis. Methods 1,306 patients with an initial t-score of –1.5 or lower were randomly assigned to receive calcium aspartate anhydrous (CalAA, 520mg elemental per day) and a placebo, or calcium citrate (1500 mg elemental per day) and vitamin D (1000 IU per day), or two placebos. Results At 3 months, the bone mineral density (BMD) at the lumbar spine had increased by a mean of 4.07% in the CalAA group, 0.64 percent in the calcium citrate group and there was no significant change in the double-placebo group. The BMD of the total hip had increased by a mean of 3.37 percent in the CalAA group. No significant change was detected in the calcium citrate group or the double-placebo group. At 12 months, lumbar spine BMD had increased by a mean of 5.66 percent in the CalAA group, while the calcium citrate group and the double-placebo group saw decline of 0.51% and 0.75% respectively. Total hip BMD had increased by a mean of 4.11 percent in the CalAA group while there was no significant change in the calcium citrate group. Total hip BMD declined by a mean of 1.17% in the double-placebo group.
Read Online (PDF)
No comments:
Post a Comment